NO965521L - N-substituert-(dihydroksyboryl)alkylpurin-, -indol- og -pyrimidinderivater som kan anvendes som inhibitorer for inflammatoriske cytokiner - Google Patents

N-substituert-(dihydroksyboryl)alkylpurin-, -indol- og -pyrimidinderivater som kan anvendes som inhibitorer for inflammatoriske cytokiner

Info

Publication number
NO965521L
NO965521L NO965521A NO965521A NO965521L NO 965521 L NO965521 L NO 965521L NO 965521 A NO965521 A NO 965521A NO 965521 A NO965521 A NO 965521A NO 965521 L NO965521 L NO 965521L
Authority
NO
Norway
Prior art keywords
indole
dihydroxyboryl
inhibitors
substituted
inflammatory cytokines
Prior art date
Application number
NO965521A
Other languages
English (en)
Other versions
NO965521D0 (no
Inventor
Bradley J Benson
Xiannong Chen
George J Cianciolo
Jose-Luis Lavandera Diaz
Khalid S Ishaq
Susan L Morris-Natschke
Ronald J Uhing
Henry Wong
Original Assignee
Macronex Inc
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macronex Inc, Univ North Carolina filed Critical Macronex Inc
Publication of NO965521D0 publication Critical patent/NO965521D0/no
Publication of NO965521L publication Critical patent/NO965521L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Nye N-substituerte (dihydroksy-boryl)alkylpurin-, -indol- og -pyri-midinderivater er blitt funnet å kunne anvendes som inhibitorer for inflamma-toriske cytokiner. De kan blant annet anvendes ved behandlingen av septisk sjokk, kakeksi, reumatoid artritt, inflammatorisk tarmsykdom, multippel sklerose og AIDS. Forbindelsene frem-stilles vanligvis ved omsetning av en bromalkylborsyre med purin-, indol-eller pyrimidinbasen.
NO965521A 1994-06-22 1996-12-20 N-substituert-(dihydroksyboryl)alkylpurin-, -indol- og -pyrimidinderivater som kan anvendes som inhibitorer for inflammatoriske cytokiner NO965521L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/264,039 US5643893A (en) 1994-06-22 1994-06-22 N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
PCT/US1995/007936 WO1995035300A1 (en) 1994-06-22 1995-06-21 N-substituted-(dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines

Publications (2)

Publication Number Publication Date
NO965521D0 NO965521D0 (no) 1996-12-20
NO965521L true NO965521L (no) 1997-02-21

Family

ID=23004300

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965521A NO965521L (no) 1994-06-22 1996-12-20 N-substituert-(dihydroksyboryl)alkylpurin-, -indol- og -pyrimidinderivater som kan anvendes som inhibitorer for inflammatoriske cytokiner

Country Status (16)

Country Link
US (1) US5643893A (no)
EP (1) EP0767793B1 (no)
JP (1) JP3805789B2 (no)
KR (1) KR970703975A (no)
AT (1) ATE224396T1 (no)
AU (1) AU2907795A (no)
CA (1) CA2193644A1 (no)
DE (1) DE69528267T2 (no)
DK (1) DK0767793T3 (no)
ES (1) ES2183877T3 (no)
FI (1) FI965141A0 (no)
HU (1) HUT76298A (no)
NO (1) NO965521L (no)
NZ (1) NZ289286A (no)
PT (1) PT767793E (no)
WO (1) WO1995035300A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010021905A (ko) * 1997-07-15 2001-03-15 노미야마 아키히콰 신규인 푸린유도체 및 그 의약용도
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
BR0012676A (pt) 1999-07-22 2003-07-01 Newbiotics Inc Métodos para tratamento de tumores resistentes a terapia
US6586429B2 (en) 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
AU2002241911B9 (en) * 2001-01-19 2007-01-25 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
ATE369853T1 (de) * 2001-03-12 2007-09-15 Avanir Pharmaceuticals Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung
US20030022864A1 (en) * 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003270426A1 (en) * 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
JP2006517213A (ja) * 2003-02-11 2006-07-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な抗コリン作用剤とＴＮＦα合成又は作用阻害剤に基づく新規な医薬組成物
JP2007501618A (ja) * 2003-08-08 2007-02-01 アバニール・ファーマシューティカルズ タンパク質輸送の選択的薬理学的阻害、および関連した、ヒト疾患を治療する方法
MY146066A (en) * 2004-07-01 2012-06-29 Microlin L C Device employing gas generating cell for facilitating controlled release of fluid into ambient environment
JP2008518923A (ja) * 2004-11-01 2008-06-05 ヌアダ，リミテッド・ライアビリティ・カンパニー 化合物およびその使用方法
WO2007134169A2 (en) * 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
WO2006050054A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006050236A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
US20090264384A1 (en) * 2004-11-01 2009-10-22 Nuada, Inc. Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
AU2009234373B2 (en) * 2008-04-09 2015-09-24 Cornell University Coferons and methods of making and using them
TW201000107A (en) * 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
EP2417115A4 (en) 2009-04-07 2012-10-31 Infinity Pharmaceuticals Inc FATTY ACID AMIDE HYDROLASE INHIBITORS
JP2012523424A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US9771345B2 (en) 2009-10-07 2017-09-26 Cornell University Coferons and methods of making and using them
CA2788587C (en) 2010-02-03 2020-03-10 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
EP2647639A1 (en) * 2012-04-06 2013-10-09 LEK Pharmaceuticals d.d. ß-boration of alkene and alkyne intermediates
EP3913068B1 (en) 2015-10-12 2023-08-02 Advanced Cell Diagnostics, Inc. In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
WO2024054934A1 (en) 2022-09-07 2024-03-14 Mdx Management Llc Shp-1 inhibitors for treating cancer
WO2024097804A1 (en) 2022-11-02 2024-05-10 Mdx Management Llc Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer
WO2024196822A1 (en) 2023-03-17 2024-09-26 Mdx Management Llc Compositions and methods for ameliorating adverse effects of therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4537773A (en) * 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
GB8926611D0 (en) * 1989-11-24 1990-01-17 Xenova Ltd Compound and its use
US5130302A (en) * 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5362732A (en) * 1989-12-20 1994-11-08 University Of North Carolina At Chapel Hill Boronated compounds
PT584347E (pt) * 1992-03-04 2003-06-30 Cell Therapeutics Inc Compostos de xantina hidroxilados enantiomericos
US5306722A (en) * 1992-09-02 1994-04-26 Bristol-Myers Squibb Company Thymidine derivatives and therapeutic method of use

Also Published As

Publication number Publication date
EP0767793A1 (en) 1997-04-16
HU9603536D0 (en) 1997-02-28
PT767793E (pt) 2003-02-28
DE69528267D1 (de) 2002-10-24
DE69528267T2 (de) 2003-04-17
US5643893A (en) 1997-07-01
EP0767793B1 (en) 2002-09-18
DK0767793T3 (da) 2002-10-14
ATE224396T1 (de) 2002-10-15
JPH10507739A (ja) 1998-07-28
CA2193644A1 (en) 1995-12-28
ES2183877T3 (es) 2003-04-01
NO965521D0 (no) 1996-12-20
JP3805789B2 (ja) 2006-08-09
FI965141A (fi) 1996-12-20
AU2907795A (en) 1996-01-15
NZ289286A (en) 1998-09-24
FI965141A0 (fi) 1996-12-20
KR970703975A (ko) 1997-08-09
HUT76298A (en) 1997-07-28
WO1995035300A1 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
NO965521D0 (no) N-substituert-(dihydroksyboryl)alkylpurin-, -indol- og -pyrimidinderivater som kan anvendes som inhibitorer for inflammatoriske cytokiner
NO965520D0 (no) Hydroksyalkylammoniumpyrimidiner eller -puriner, og nukleosidderivater, som kan anvendes som inhibitorer for inflammatoriske cytokiner
PT1070056E (pt) Inibidores de pde iii/iv a base de ftalazinona
AU2003248978A1 (en) Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
DK1109785T3 (da) Indolderivater og deres anvendelse til behandling af ondartede og andre sygdomme forårsaget af patologisk celleproliferation
UA74370C2 (uk) Піроло(2,3-d)піримідинові сполуки як імуносупресори
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
EA200200510A1 (ru) 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр
HRP20050382B1 (hr) Novi pirimidin-4,6-dikarboksamidi za selektivnu inhibiciju kolagenaza
MXPA04004263A (es) Hidrazono-malonitrilos.
EA200000628A1 (ru) Ингибиторы металлопротеаз матрикса
ITMI20021495A1 (it) Procedimento per la preparazione di copolimeri a blocchi.
CO5180536A1 (es) Inhibidores de proteasas catepsina
AU2003236834A1 (en) Hydroxamic acid derivatives
EA200101096A1 (ru) Применение производных мадурафталазина в качестве ингибиторов провоспалительных цитокинов
MXPA04004010A (es) Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz.
PT1294729E (pt) 2-aminoalquil-tieno[2,3-d]pirimidinas
CO5080805A1 (es) NUEVOS DERIVADOS DE ACIDO CARBOXILICO ASIMETRICAMENTE SUSTITUIDOS, SU OBTENCION Y USO COMO ANTAGONISTAS DE LOS RECEPTORES DE ET[sub A]/ET[sub B] MIXTOS
IL169334A0 (en) Phthalazine derivatives as phosphodiesterase 4 inhibitors
AP2002002464A0 (en) 3- Heterocyclyl propanohydroxamic acid PCP inhibitors.
AU1875283A (en) Derivatives of n - (4-phenylcyclohexyl) glycines